NASDAQ:STOK Stoke Therapeutics (STOK) Stock Forecast, Price & News $4.18 +0.03 (+0.72%) (As of 09/22/2023 08:52 PM ET) Add Compare Share Share Today's Range$4.08▼$4.3050-Day Range$4.15▼$11.9952-Week Range$4.08▼$16.48Volume229,300 shsAverage Volume335,579 shsMarket Capitalization$184.99 millionP/E RatioN/ADividend YieldN/APrice Target$23.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Stoke Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside462.2% Upside$23.50 Price TargetShort InterestBearish15.99% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.72Based on 2 Articles This WeekInsider TradingSelling Shares$159,000 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.58) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector294th out of 963 stocksPharmaceutical Preparations Industry121st out of 452 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $23.50, Stoke Therapeutics has a forecasted upside of 462.2% from its current price of $4.18.Amount of Analyst CoverageStoke Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted15.99% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in Stoke Therapeutics has recently increased by 3.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 2.1 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Stoke Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for STOK on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $159,000.00 in company stock.Percentage Held by Insiders12.70% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.58) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -1.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 0.89. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Stoke Therapeutics (NASDAQ:STOK) StockStoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.Read More STOK Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesSeptember 21, 2023 | finance.yahoo.comStoke Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 20, 2023 | finance.yahoo.comStoke Therapeutics Appoints Ian Smith to its Board of DirectorsSeptember 25, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.September 10, 2023 | seekingalpha.comStoke Therapeutics Is Unable To Derisk Its PlatformSeptember 6, 2023 | markets.businessinsider.comStoke Therapeutics (STOK) Receives a Buy from BTIGSeptember 5, 2023 | finance.yahoo.comStoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy CongressAugust 16, 2023 | finance.yahoo.comThis Under-the-Radar Growth Stock Could Soar by 277%, According to Wall StreetAugust 8, 2023 | finance.yahoo.comStoke Therapeutics Second Quarter 2023 Earnings: Misses ExpectationsSeptember 25, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 7, 2023 | msn.comStoke Therapeutics GAAP EPS of -$0.69 misses by $0.06August 7, 2023 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Lags Revenue EstimatesAugust 3, 2023 | msn.comStoke Therapeutics (STOK) Price Target Decreased by 13.91% to 22.44August 2, 2023 | finance.yahoo.comStoke Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth ConferenceAugust 2, 2023 | finance.yahoo.comWhy Shares of Stoke Therapeutics Plummeted TuesdayJuly 31, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Stoke TherapeuticsJuly 26, 2023 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Stoke Therapeutics (STOK)July 25, 2023 | msn.comStoke Therapeutics (NASDAQ:STOK) Tanks on New Clinical Data in Dravet SyndromeJuly 25, 2023 | markets.businessinsider.comWhy Stoke Therapeutics Is Trading Lower Today?July 25, 2023 | marketwatch.comStoke Therapeutics Shares Drop to All-Time Low on STK-001 Study DataJuly 25, 2023 | markets.businessinsider.comStoke Reports Safety And Efficacy Data From Phase 1/2a Studies Of STK-001 In Dravet SyndromeJuly 25, 2023 | finance.yahoo.comStoke Therapeutics Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet SyndromeJuly 21, 2023 | finance.yahoo.comStoke Therapeutics to Host Webinar to Present New Data from Patients Treated with STK-001 in the Phase 1/2a Studies (MONARCH & ADMIRAL) and the SWALLOWTAIL Open-Label Extension (OLE) Study in Children and Adolescents with Dravet SyndromeJuly 7, 2023 | benzinga.comStoke Therapeutics Insider Trades Send a SignalJuly 5, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn SituationJune 26, 2023 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About Stoke TherapeuticsJune 16, 2023 | finance.yahoo.comStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)June 14, 2023 | finance.yahoo.comShould You Buy Stoke Therapeutics, Inc. (STOK) After Golden Cross?See More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address STOK Company Calendar Last Earnings8/07/2023Today9/24/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees117Year FoundedN/APrice Target and Rating Average Stock Price Forecast$23.50 High Stock Price Forecast$35.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+462.2%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,070,000.00 Net Margins-679.83% Pretax Margin-1,186.72% Return on Equity-52.94% Return on Assets-39.15% Debt Debt-to-Equity RatioN/A Current Ratio11.28 Quick Ratio11.28 Sales & Book Value Annual Sales$12.40 million Price / Sales14.92 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book0.89Miscellaneous Outstanding Shares44,260,000Free Float38,636,000Market Cap$185.01 million OptionableNot Optionable Beta0.35 The Best High-Yield Dividend Stocks for 2023Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 74)Ph.D., CEO & Director Comp: $931.21kDr. Adrian R. Krainer Ph.D. (Age 64)Co-Founder & Independent Director Comp: $44kMr. Stephen J. Tulipano CPA (Age 64)CPA, MBA, Chief Financial Officer Comp: $619.09kDr. Barry S. Ticho FACC (Age 62)M.D., Ph.D., Chief Medical Officer Comp: $688.83kMs. Isabel Aznarez Ph.D. (Age 50)Co-Founder & Group VP of Discovery Research Dr. Huw M. Nash Ph.D. (Age 56)COO & Chief Bus. Officer Mr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 33)Corp. Sec. & Gen. Counsel Ms. Dawn Kalmar (Age 45)Chief Communications Officer Ms. Joan WoodChief HR OfficerMore ExecutivesKey CompetitorsGossamer BioNASDAQ:GOSSCorMedixNASDAQ:CRMDAstria TherapeuticsNASDAQ:ATXSALX OncologyNASDAQ:ALXOAllakosNASDAQ:ALLKView All CompetitorsInsiders & InstitutionsBarclays PLCSold 8,031 shares on 9/21/2023Ownership: 0.034%Virginia Retirement Systems ET ALBought 15,600 shares on 8/22/2023Ownership: 0.035%California State Teachers Retirement SystemBought 4,498 shares on 8/21/2023Ownership: 0.060%Nuveen Asset Management LLCBought 7,568 shares on 8/16/2023Ownership: 0.144%Wells Fargo & Company MNBought 6,516 shares on 8/15/2023Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions STOK Stock - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price forecast for 2023? 9 brokerages have issued 1-year price objectives for Stoke Therapeutics' stock. Their STOK share price forecasts range from $12.00 to $35.00. On average, they expect the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 462.2% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2023? Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK stock has decreased by 54.7% and is now trading at $4.18. View the best growth stocks for 2023 here. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06. The company earned ($2.48) million during the quarter, compared to analysts' expectations of $4 million. Stoke Therapeutics had a negative net margin of 679.83% and a negative trailing twelve-month return on equity of 52.94%. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and Simplify Propel Opportunities ETF (SURI).Global X Genomics & Biotechnology ETF (GNOM). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Stoke Therapeutics' stock symbol? Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK." Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cowen AND Company LLC (8.42%), BlackRock Inc. (5.18%), Geode Capital Management LLC (1.36%), State Street Corp (1.25%), Granahan Investment Management LLC (1.20%) and M28 Capital Management LP (0.78%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Jonathan Allan and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Stoke Therapeutics' stock price today? One share of STOK stock can currently be purchased for approximately $4.18. How much money does Stoke Therapeutics make? Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $185.01 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis. How many employees does Stoke Therapeutics have? The company employs 117 workers across the globe. How can I contact Stoke Therapeutics? Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com. This page (NASDAQ:STOK) was last updated on 9/25/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.